🇺🇸 FDA
Pipeline program

Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

XMDYYYXYK-12

Phase 2 small_molecule active

Quick answer

Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections for Hematological Malignancy is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Hematological Malignancy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials